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Pharmacogenomic testing has become increasingly widespread. However, there 
remains a need to bridge the gap between test results and providers lacking the 
expertise required to interpret these results. The Indiana Genomics Implementation 
trial is underway at our institution to examine total healthcare cost and patient 
outcomes after genotyping in a safety-net healthcare system. As part of the study, 
trial investigators and clinical pharmacology fellows interpret genotype results, review 
patient histories and medication lists and evaluate potential drug–drug interactions. 
We present a case series of patients in whom pharmacogenomic consultations aided 
providers in appropriately applying pharmacogenomic results within the clinical 
context. Formal consultations not only provide valuable patient care information but 
educational opportunities for the fellows to cement pharmacogenomic concepts.
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The Indiana Genomics Implementation 
(INGENIOUS) trial was initiated to exam-
ine the impact of genotyping and subsequent 
genotype-driven changes in care on total 
healthcare cost and long-term outcomes 
in a low income, safety-net population [1]. 
Subjects are genotyped for approximately 
40 variants in response to a new prescription 
of 1 of 28 drugs. Although the electronic 
medical record (EMR) system is capable of 
delivering general recommendations through 
automated interruptive alerts for future pre-
scriptions, the computer algorithms are not 
yet sophisticated enough to account for inci-
dental findings related to existing prescrip-
tions, concomitant drug–drug interactions 
(DDIs), or drug–disease interactions. These 
EMR alerts are also not present for the ini-
tial prescription that prompted trial enroll-
ment since genotyping is completed 1 week 
following enrollment.
A component of the study is the 
Adjudication Committee, composed of a 
study principal investigator, a physician, and 
a clinical pharmacology fellow. The Com-
mittee is supported by a pharmaco genomics 
consult physician with clinical pharma-
cology hospital privileges. The Committee 
meets on a weekly basis to review pharmaco-
genomic results generated by the trial; fel-
lows are responsible for pre-reviewing the 
patients’ genotypes, demographics, clinical 
history, medication profiles and adverse drug 
responses. These data are then reviewed by 
the committee and recommendations are 
made regarding medication choice and dos-
age for any medications that may be affected 
by genotype results or known DDIs. Any 
patient with a significant actionable muta-
tion or complicated clinical picture is 
referred to the consult physician and a for-
mal consult ation is performed. The fellow 
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typically prepares the consult note and reviews it with 
the supervising physician, evaluating the patient in 
person if necessary. We present a series of four patients 
for whom formal consult services were provided, illus-
trating both medi cations with well-known guidelines 
and medications for which established guidelines do 
not exist. Details of the INGENIOUS trial have been 
previously published [1,2]. The INGENIOUS trial was 
approved by the Indiana University IRB and is reg-
istered on Clinical Trials.gov (NCT02297126). The 
trial is ongoing with a projected completion date of 
June 2018.
Case 1: citalopram
Case 1 provides an important example in which fol-
lowing the Clinical Pharmacogenetics Implementa-
tion Consortium (CPIC) guidelines proved chal-
lenging for a patient prescribed citalopram. The 
guidelines recommended selecting an alternative 
agent to citalopram based on the patient’s geno-
type. However, prior alternate agent inefficacy and 
possible DDIs limited practical therapeutic options.
A 54-year-old male patient presented to the neuro-
logy clinic with chronic encephalopathy following 
a motor vehicle accident that occurred 2 years prior 
to trial enrollment. The patient had been previously 
evaluated in the outpatient neurology clinic with 
symptoms of memory loss, depression and anxiety. 
His response to venlafaxine (Effexor® [Pfizer, NY, 
USA]) therapy was inadequate. As a result, the patient 
was tapered from venlafaxine and citalopram (Cel-
exa® [Forest Laboratories, Inc., NY, USA], a selective 
serotonin reuptake inhibitor, SSRI) was prescribed as 
a replacement, prompting enrollment in the INGE-
NIOUS trial and acquisition of his geno type. The 
neurology team requested a consult in response to 
the patient’s CYP2C19 ultrarapid metabolizer status 
and poor response to prior venlafaxine therapy.
Concomitant medications included donepezil 
(Aricept® [Pfizer, NY, USA]), lisinopril (Zestril® 
[AstraZeneca, Cambridge, UK]), and glipizide (Glu-
cotrol® [Pfizer, NY, USA]). Lab oratory and physical 
findings were unremarkable and noncontributory to 
selection of an appropriate antidepressant agent.
Pharmacogenetic testing revealed that this patient 
is homozygous for the CYP2C19*17 allele indicat-
ing that two gain-of-function alleles are present. 
The prevalence of the *17 allele varies widely across 
populations: it is reported at <5% frequency in 
popu lations of Asian descent and >20% frequency 
in Cauc asian, eastern European and African popu-
lations [3]. A major side effect of citalopram is its cor-
rected QT interval (QT
c
) prolongation. The CPIC 
guidelines for this mutation suggest use of an 
alternative drug not predominantly metabolized by 
CYP2C19 (Level of evidence: moderate) [4] while 
the Royal Dutch Association for the Advancement 
of Pharmacy – Pharmacogenetics Working Group 
(DPWG) guidelines suggest therapeutic drug moni-
toring in conjunction with dose titration to a maxi-
mum of 150% of the typical therapeutic dose [5]. 
According to the DPWG, dose titrations are recom-
mended based upon clinical efficacy or adverse events 
with a recommendation to select an alternative agent 
upon occurrence of the later at maximal dosages. 
Alternative agents not metabolized predominantly 
by CYP2C19 include paroxetine (Paxil® [Glaxo-
SmithKline, London, UK]) and bupropion (Well-
butrin® [Glaxo SmithKline]). Because this patient 
was already taking a stable dose of donepezil, parox-
etine and bupropion may not be ideal options for this 
patient as they are potent inhibitors of CYP2D6, the 
enzyme that metabolizes donepezil, CYP2D6. How-
ever, there is limited evidence to support the clinical 
relevance of this DDI.
One potential drug–disease interaction includes 
the evidence for the use of methylphenidate in 
patients with traumatic brain injury [6–8]. Ulti-
mately the consult service recommended switching 
antidepressant agents to a drug not metabolized 
predominantly by CYP2C19 or titration of the cital-
opram dosing beyond typical dosing requirements 
in an attempt to overcome the patient’s ultrarapid 




This case illustrates two key points. The first is 
that the CPIC and DPWG guidelines do not always 
align. In this circumstance, the consult team fol-
lowed the CPIC guidelines, recommending drug 
substitution rather than dose titration. A second 
key point is that it is not always straightforward to 
recommend an alternative agent. In this case the 
patient had previously failed venlafaxine therapy 
and had potential drug interactions with donepezil, 
significantly limiting therapeutic options.
Importantly, the patient and primary care pro-
vider both were provided with the pharmaco genetics 
results and educated about potential implications 
for future prescribing. Specifically the provider was 
notified of a potential increased bleeding risk that 
should be carefully considered if prescribing clopi-
dogrel (Plavix® [Sanofi-Aventis, NJ, USA]) in the 
future [9]. This patient was also found to have a 
reduced activity variant in the SLCO1B1 gene which 
would be relevant to future statin prescriptions, par-
ticularly simvastatin (Zocor® [Merck and Co., Inc., 
NJ, USA]), as this patient could be at increased risk 
for statin-induced myopathy.
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Case 2: clopidogrel
Case 2 illustrates how pharmacogenomic testing can 
retrospectively explain significant adverse events, 
reinforcing the need for alternative agent selection. 
It also relays the importance of considering DDIs 
with drug–gene interactions.
A 65-year-old woman with a past medical history 
of diabetes mellitus, hypertension, chronic obstructive 
pulmonary disease, gastro-esophageal reflux disease, 
and coronary artery disease presented with recurrent 
chest pain. Two years prior, the patient underwent a 
percutaneous coronary intervention with placement 
of a drug-eluting stent in her left anterior descending 
(LAD) coronary artery. She was started on the anti-
coagulant clopidogrel, an inhibitor of platelet adenosine 
diphosphate receptors. Within 30 days of revascular-
ization, the patient experienced stent thrombosis asso-
ciated with a ST-elevation myocardial infarction and 
culminating in a single vessel coronary artery bypass 
graft. Now, 2 years later, the patient again underwent a 
left heart catheterization with balloon angioplasty and 
stent placement in her LAD graft. She was once again 
prescribed clopidogrel. The clopidogrel order triggered 
trial enrollment followed by pharmacogenomic testing 
revealing a CYP2C19 *1/*2 genotype. The patient’s 
primary provider requested a formal consult to better 
understand the implications of this genotype.
The combination of one functional allele (*1) and 
one loss-of-function allele (*2) predicts that this patient 
has reduced CYP2C19 metabolic activity. Reduced 
CYP2C19 activity impairs conversion of clopidogrel to 
the pharmacologically active metabolite responsible for 
inhibition of platelet aggregation. Dose escalation for 
patients with reduced CYP2C19 function may over-
come the lack of platelet aggregation inhibition but 
does not appear to translate to improved patient out-
comes [10,11]. As a result, both CPIC and DPWG guide-
lines recommend that patients with reduced CYP2C19 
activity receive alternative antiplatelet therapy [5,12]. 
Ultimately, antiplatelet agent selection depended upon 
consideration of the patient’s CYP2C19 genotype in 
addition to individual clinical characteristics.
Diabetes mellitus Type 2 with poor control, hyper-
tension, and a long smoking history are likely to con-
tribute to high residual platelet aggregation for this 
patient, further underscoring the importance of opti-
mal antiplatelet therapy. The patient’s medication list 
at the time of genotyping consisted of 23 additional 
medications including esomeprazole (Nexium® [Astra-
Zeneca, Cambridge, UK]). Esomeprazole inhibition 
of CYP2C19 in conjunction with reduced CYP2C19 
activity may further decrease the metabolic activ ation 
of clopidogrel. The combination of disease–drug, 
drug–drug and gene–drug interactions placed this 
patient at high risk for clopidogrel therapeutic failure. 
As a result, the consult committee recommended use 
of an alternative agent such as prasugrel (Effient® [Eli 
Lilly and Company, IN, USA]) or ticagrelor (Brilinta® 
[AstraZeneca]). Although platelet reactivity testing 
can be used to determine the degree of platelet inhibi-
tion resulting from anticoagulation therapy, reduction 
in bleeding events has not been shown after medic-
ation adjustments and further information is needed 
regarding the utility of routine use of these tests in 
patient care [13].
The majority of medication changes recommended 
by the consult service fall within our health system’s 
formulary. Prasugrel is an exception but is available 
through patient assistance programs with prior author-
ization. The patient and provider are not burdened by 
the medication cost, but the health system is impacted 
by the cost.
Case 3: tramadol
Case 3 demonstrates an important rationale for 
pharmaco-genotyping patients receiving codeine or 
tramadol for pain management. The patient’s primary 
service requested a pharmacogenomics consult to 
interpret genomic results after encountering difficulty 
achieving pain control.
A 67-year-old Caucasian male with a history of bilat-
eral venous stasis ulcers of the ankles had been admit-
ted for debridement with Integra™ Matrix Wound 
Dressing placement and subsequently developed a 
wound infection. Outpatient treatment was ineffect-
ive and he was readmitted for parenteral antibiotic 
therapy. During his admission, he received tramadol 
(Ultram® [Ortho-McNeil Pharmaceutical, Inc., NJ, 
USA]) for pain; the tramadol order triggered his study 
enrollment. He was found to have a CYP2D6 mut-
ation consistent with a reduced metabolism phenotype 
and his pain had been difficult to control over the long 
course of his ulcer treatment; a consult was requested 
to assist in determination of a pain control regimen.
On review of his medical record, the patient’s medi-
cation list included acetaminophen (Tylenol® [John-
son & Johnson, NJ, USA]), aspirin (81 mg), hydro-
codone/acetaminophen (Vicodin® [AbbVie Inc., IL, 
USA), oxycodone (OxyContin® [Purdue Pharma, CT, 
USA]) and tramadol, a synthetic low potency opioid 
pain medication. His serum creatinine was 1.36 mg/dl 
with an eGFR of 52 ml/min and a recent ECG showed 
a QTc of 473 ms. Pharmacogenomic testing revealed a 
CYP2D6 *4/*41 genotype.
The patient’s slightly prolonged QTc were discussed 
in relation to other medications but was not pertinent 
to his pain regimen. It was confirmed that the trama-
dol was ordered at the recommended extended dosing 
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interval of every 12 h for patients with reduced kidney 
function [14]. Also included in his consult note were 
three low level DDIs; concomitant use of tramadol 
with opioids and the resulting decreased seizure thresh-
old was discussed [15]. The patient was not taking any 
known CYP2D6 inhibitors.
The CYP2D6 *4 allele is a nonfunctional allele and 
the *41 allele is a reduced function allele. These alleles 
combined equal an activity score of 0.5 [16] and con-
fer a reduced function phenotype. The activity scor-
ing system for CYP2D6 was generated from analyses 
of paired genotype and phenotype information and 
provides a method of predicting phenotype based on 
specific known alleles. A score is assigned to each allele 
(0, 0.5, 1 or 2) based on published phenotype data 
and the activity score for the individual is the sum of 
the scores of both alleles. Given that CYP2D6 plays a 
role in the metabolism of a multitude of clinically use-
ful medications [17], including codeine, hydrocodone, 
oxycodone and tramadol, this may explain at least in 
part the patient’s difficulty achieving pain control: he 
may not be experiencing the full benefit of his anal-
gesic medications. These medications are metabolized 
in part by CYP2D6 into active metabolites with higher 
binding affinity to opioid receptors than the parent 
compounds and reduced or defective CYP2D6 meta-
bolic status may result in less than the expected level of 
analgesia. Current evidence only exists regarding the 
association of poor metabolizer phenotypes (two non-
functional alleles) and reduced response to pain medi-
cations [18,19], but on an individual level, these genetic 
results may help explain the patient’s lack of response 
and provide guidance for alternative therapies. Hydro-
codone is the least affected by CYP2D6 mutations 
as alternative metabolic pathways exist; morphine 
is active as the parent compound and thus response 
should not be affected; transdermal and transmucosal 
fentanyl (Duragesic® [Janssen Pharmaceuticals, Inc., 
NJ, USA], Actiq® [Teva Pharmaceutical Industries 
Ltd., Petah Tikva, Israel]) are metabolized primarily 
via CYP3A4 [20] and would be reasonable alternatives.
This case demonstrates an important rationale for 
pharmacogenotyping patients receiving codeine or tra-
madol for pain management. The patient’s pain was 
not controlled on tramadol therapy alone. Geno typing 
supported the escalation of pain management with 
hydrocodone. Although this patient did not convey 
nonadherence or drug-seeking behavior, providers may 
include these behaviors on their differential of uncon-
trolled pain, disproportionate to their expectations. At 
times, a history is insufficient to distinguish patients 
with persistent pain and those with drug-seeking 
behavior [21]. Genotyping provides an additional 
rationale for escalation of pain management and may 
expedite opiate titration for future episodes of signif-
icant pain by bypassing those medications known to 
be ineffectively metabolized [22–24].
Case 4: venlafaxine
Case four reveals a potential limitation of pharmaco-
genomic testing, wherein the patient’s genotype pre-
dicted adverse effects to an existing venlafaxine pre-
scription, but the patient had maintained a favorable 
clinical response for some time. The primary care 
provider questioned how to properly utilize these 
results.
A 50-year-old white woman was evaluated by her 
primary care physician for depression. She had recently 
changed primary providers and health systems. She 
reported a history of past depression; other medical 
issues included essential hypertension, iron deficiency 
anemia, obesity and gastroesophageal reflux. As a result 
of this visit, the provider renewed the patient’s anti-
depressant venlafaxine (a serotonin-norepinephrine 
reuptake inhibitor [SNRI]). Since this was an initial 
venlafaxine prescription in our health system, the 
order prompted study enrollment.
This patient’s CYP2D6 mutation (*5/*29) predicts 
a reduced function metabolizer phenotype with an 
activity score of 0.5 [16]. The *5 allele is a complete 
deletion mutation and in combination with the *29 
allele (results in a reduced function protein) predicts 
decreased CYP2D6 activity. The primary meta-
bolic pathway for venlafaxine (VEN) is via CYP2D6 
into O-desmethylvenlafaxine (ODV) during first 
pass hepatic metabolism. ODV is also active as an 
SNRI; better treatment response has been shown to 
be associated with a higher ODV/VEN ratio [25,26] 
and patients with low ODV/VEN ratios may have 
an unfavorable adverse effect profile [27]. The DPWG 
recommends that an alternate drug be chosen for 
patients with predicted poor or intermediate pheno-
type as there is insufficient data available to calcu-
late dose adjustment based on genotype [5]; if ven-
lafaxine is prescribed, the dose should be carefully 
titrated to clinical response and ODV levels should 
be monitored (level of evidence: 4, good).
This patient was also taking amlodipine (Norvasc® 
[Pfizer Inc., NY, USA]), ferrous sulfate (Feosol® [Meda 
Consumer Healthcare, NJ, USA]) and omeprazole. 
No other drug–gene interactions were identified. Her 
serum creatinine was 0.7 mg/dl and liver function 
testing was normal. An electrocardiogram was not 
available.
The consult service recommended no change in med-
ications: the patient reported that she had tolerated the 
medication in the past, though she did not remember 
the dose. Her clinical response and lack of side effects 
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may be influenced by several factors: she may have suf-
ficient CYP2D6 activity to exhibit a normal phenotype 
for this particular drug-gene pair, her severity of symp-
toms may only necessitate a low level of active drug, she 
may have a high tolerance for the known side effects of 
venlafaxine, and/or she may have sufficient shunting 
through alternate metabolic pathways (e.g., CYP2C19) 
to produce a favorable ODV/VEN ratio and relieve 
her symptoms. Though her CYP2C19 genotype is nor-
mal, it is important to realize that she is now taking 
omeprazole, a known CYP2C19 inhibitor.
This case illustrates the need for interpretive services 
when pharmacogenetic information is available as mul-
tiple variables contribute to an individual’s response to 
treatment. In this example, the patient’s prior tolerance 
of venlafaxine outweighs the pharmaco genotyping 
result predicting adverse effects to venlafaxine. The 
patient’s new primary care provider questioned how to 
properly utilize the genotype results. She felt more com-
fortable making the decision to continue venlafaxine 
after a pharmacogenomics consultation concurred with 
her assessment that the patient had a favorable clini-
cal response with acceptable tolerance. The patient’s 
prescription would not have been questioned without 
pharmacogenomic testing, and this is a cautionary 
example to avoid over-reliance on testing results.
If the patient did develop intolerable side effects or 
did not respond to venlafaxine, possible alternatives 
include sertraline (Zoloft® [Pfizer Inc., NY, USA]) and 
citalopram. As these are metabolized predominantly by 
CYP2C19, the patient should be switched to an alternate 
proton pump inhibitor known to have less CYP2C19 
inhibitory activity (e.g., pantoprazole, Protonix® 
[Pfizer Inc.]) or to an alternate acid suppression agent 
(e.g., ranitidine, Zantac® [Pfizer Inc.]).
Discussion
Other large-scale pharmacogenomics implementations 
exist [28] but the INGENIOUS trial is the only one in 
the USA to specifically enroll an underserved popu-
lation and to target a large number of medications with 
genotyping results available in the patient medical 
record to all providers. Our study is also, to our know-
ledge, the only one that reviews each set of results in 
the context of the individual clinical situation in order 
to provide information about the primary medication 
of interest as well as incidental findings related to other 
medications and DDIs. Automated systems are excel-
lent for reporting genotypes or gene-drug pairs with 
solid evidence to guide drug choice and dose such as 
CYP2C9 influences on warfarin (Coumadin) dose [29]. 
Such systems can streamline the return of information 
to the EMR [30] and the INGENIOUS study alerts 
providers to drug–gene interactions through the EMR. 
However, individual review is necessary because these 
automated systems are not yet sophisticated enough to 
interpret gene-drug pair recommendations in concert 
with drug–drug and drug–disease interactions.
Another well-known issue addressed by our 
structure is the interpretation of results by provid-
ers who have not been trained in this area and/or 
who have limited experience and are not comfort-
able with the translation of genotyping data into 
patient care recommend ations and clinical decision-
making [31–33]. Our Committee bridges this gap and 
provides not only the pertinent information but is 
available for further provider support if needed [1].
The Committee serves a dual purpose in our project: 
it also provides a training and educational opportunity 
for the NIH-sponsored Clinical Pharmacology Fellows. 
Fellows improve their understanding of drug–gene 
interactions and metabolism pathways during their 
prereview of patient information and genotype results. 
The review of data with the project PI and faculty phys-
ician creates an active learning experience that makes 
pharmacogenomics more relevant, illustrates concepts 
learned in didactic curricula, and provides continued 
exposure that may lead to increased retention of inform-
ation. Others have shown that involvement of trainees 
in active interpretation of genotype results leads to a 
more favorable experience and increased knowledge 
gain [34–36]; our study, however, avoids the ethical and 
philosophical sticky wickets that are inherent with 
using one’s own DNA for genotyping.
The INGENIOUS study also provides our fellows 
with a service learning modality: enrollment data, 
medication lists, genotype results and formal consult 
notes are maintained within a REDCap (Research 
Electronic Data Capture) database [37]. REDCap is a 
secure, web-based application designed to support data 
capture for research studies. Our REDCap database 
was created by and is continually curated by the fel-
lows to review and document all patient genotyping 
results, even those that do not result in a formal clini-
cal pharma cology consult. This responsibility allows 
the fellows to gain practical understanding of the 
logistics of a large pharmacogenomic trial.
In this case series, we present four varied examples 
of patients with clinically actionable genotypes that 
illustrate both the educational value for the fellows and 
the impact of pharmacogenomics testing at the patient 
level. Though the INGENIOUS trial is ongoing, we 
provide a brief overview of the logistics of reviewing 
genotype data obtained as part of the study. A signifi-
cant limitation of this study is that clinical outcomes 
have not yet been assessed; thus, caution should be 
exercised when interpreting the data in this case series 
until the study itself is published.
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We illustrate the uniqueness of the INGENIOUS 
trial in that the Clinical Pharmacology Fellows are 
critically involved in the process of reviewing genotype 
data and making clinical recommendations. The Adju-
dication Committee provides critical applied learning 
opportunities for the Fellows as we have outlined in 
this case series. We also demonstrate the value of our 
unique Adjudication Committee in assessing multiple 
aspects of the clinical situation for each individual 
patient. As shown by our example cases, clinical situ-
ations are often complex and genotype information 
must be considered in the context of the larger clinical 
picture. The final outcomes of the INGENIOUS trial 
will provide insight regarding the impact of genotyping 
on long-term outcomes and healthcare expenditure at 
the population level, in this series we provide examples 
of the impact of genotyping at an individual level.
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